Global Severe Acne Vulgaris Treatment Market Report and Forecast 2023-2031

Global Severe Acne Vulgaris Treatment Market Report and Forecast 2023-2031

Global Severe Acne Vulgaris Treatment Market Outlook

The global severe acne vulgaris treatment market growth can be attributed to the increasing prevalence of severe acne vulgaris, the development of novel therapies, and the rising demand for effective treatment options. The prevalence of acne vulgaris is likely to grow at a CAGR of 1.73% in the forecast period of 2023-2031.

Severe Acne Vulgaris Treatment Market: Introduction

Acne vulgaris is a common skin disorder that affects approximately 9.4% of the global population. Severe acne vulgaris is a more severe form of the condition, characterized by deep, painful nodules and cysts. The treatment of severe acne vulgaris typically involves a combination of topical and oral medications, including retinoids, antibiotics, and hormonal therapies. In severe cases, isotretinoin may be prescribed, although this medication carries significant side effects and requires close monitoring.

The report by Expert Market Research provides a comprehensive analysis of the severe acne vulgaris treatment market, including market size, growth, and trends. The report covers the market for severe acne vulgaris treatment, including drugs and therapies used for the treatment of the condition.

Severe Acne Vulgaris Epidemiology

Severe acne vulgaris is a prevalent condition, affecting millions of people worldwide. The condition is more common in adolescents and young adults, although it can affect individuals of all ages. Severe acne vulgaris can cause significant physical and psychological distress and can have a negative impact on an individual's quality of life.

The treatment of severe acne vulgaris typically involves a combination of topical and oral medications, including retinoids, antibiotics, and hormonal therapies. In severe cases, isotretinoin may be prescribed, although this medication carries significant side effects and requires close monitoring. Other treatment options for severe acne vulgaris include chemical peels, laser therapy, and photodynamic therapy.

As the global population continues to grow and the prevalence of severe acne vulgaris rises, the demand for effective treatment options is expected to increase. This is expected to drive the growth of the severe acne vulgaris treatment market, as healthcare providers seek new and innovative therapies to manage this debilitating condition.

Severe Acne Vulgaris Treatment Market Segmentations

The market can be categorised into drugs, type, treatment method, age group, distribution channel, treatment channel, and region.

Market Breakup by Drugs

• Prescription Medicines
• Over-the-Counter Medicines

Market Breakup by Type

• Non-Inflammatory Acne
• Inflammatory Acne

Market Breakup by Treatment Method

• Systemic Therapy
• Hormonal Therapy
• Oral Contraceptive
• Spironolactone
• Cyproterone Acetate
• Flutamide
• Topical Antibiotics
• Erythromycin
• Clindamycin
• Clarithromycin
• Azithromycin
• Nadifloxacin
• Topical Retinoids
• Adapalene
• Tazarotene
• Tretinoin
• Isotretinoin
• Metretinide
• Retinaldehyde
• Beta-Retinoyl Glucuronide
• Physical Treatment
• Lesion Removal
• Phototherapy
• Topical Combination Therapy
• Chemical Peeling
• Glycolic Acids Peel
• Salicylic Acid Peel
• Pulsed Dye Laser Treatment
• Others

Market Breakup by Age Group

• 10-17 years
• 18-40 years
• 40-65 years
• 65 and Above

Market Breakup by Distribution Channel

• Derma Clinics
• Pharmacy
• E-Commerce

Market Breakup by Treatment Channel

• Public
• Private

Severe Acne Vulgaris Treatment Market Breakup by Region

• North America
• United States of America
• Canada
• Europe
• United Kingdom
• Germany
• France
• Italy
• Others
• Asia Pacific
• China
• Japan
• India
• ASEAN
• Australia
• Others
• Latin America
• Brazil
• Argentina
• Mexico
• Others
• Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Severe Acne Vulgaris Treatment Market Scenario

The market is expected to experience steady growth during the forecast period of 2023-2031. The key drivers of the market include the increasing prevalence of severe acne vulgaris, the development of novel therapies, and the rise in healthcare expenditure. However, the availability of over-the-counter acne treatments and the potential side effects associated with prescription medications are likely to hinder the growth of the market.

North America dominates the severe acne vulgaris treatment market, followed by Europe and the Asia Pacific. The high prevalence of severe acne vulgaris in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for severe acne vulgaris treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the condition and the rising healthcare expenditure in the region.

The market for severe acne vulgaris treatment can be categorized into various segments, including treatment type, distribution channel, and end-user. The most used treatment types for severe acne vulgaris include topical medications and oral medications. In terms of distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Key Players in the Global Severe Acne Vulgaris Treatment Market

The report gives an in-depth analysis of the key players involved in the severe acne vulgaris treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• AbbVie, Inc (Allergen)
• Botanix Pharmaceuticals Ltd.
• Galderma S.A.
• Bausch Health Companies Inc.
• GlaxoSmithKline Plc.
• Johnson & Johnson Services Inc.
• Almirall S.A.
• Hospira, Inc.
• Viatris (Mylan N.V.)
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• Perrigo Company Plc.
• Boston Scientific Corporation (Lumenis)